NASDAQ:VRTX - Vertex Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $277.68
  • Forecasted Upside: 2.53 %
  • Number of Analysts: 18
  • Breakdown:
  • 0 Sell Ratings
  • 8 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$270.84
▲ +2.36 (0.88%)

This chart shows the closing price for VRTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vertex Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VRTX

Analyst Price Target is $277.68
▲ +2.53% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $277.68, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 2.53% upside from the last price of $270.84.

This chart shows the closing price for VRTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 18 contributing investment analysts is to buy stock in Vertex Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 22 buy ratings
  • 9 hold ratings
  • 0 sell ratings
11/30/2020
  • 0 strong buy ratings
  • 19 buy ratings
  • 9 hold ratings
  • 0 sell ratings
2/28/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 8 hold ratings
  • 0 sell ratings
5/29/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 10 hold ratings
  • 0 sell ratings
8/27/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 8 hold ratings
  • 0 sell ratings
11/25/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 8 hold ratings
  • 0 sell ratings
2/23/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 8 hold ratings
  • 0 sell ratings
4/24/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 8 hold ratings
  • 0 sell ratings
5/24/2022

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 8 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/23/2022SVB LeerinkInitiated CoverageMarket Perform$265.00High
5/6/2022Wells Fargo & CompanyBoost Price Target$300.00 ➝ $305.00Medium
5/6/2022Robert W. BairdDowngradeOutperform ➝ Neutral$250.00Medium
5/6/2022Piper SandlerLower Price Target$249.00 ➝ $242.00Medium
5/3/2022Morgan StanleyUpgradeUnderweight ➝ Equal Weight$250.00Medium
4/21/2022Piper SandlerBoost Price TargetNeutral$245.00 ➝ $249.00High
4/13/2022UBS GroupBoost Price Target$258.00 ➝ $325.00High
4/5/2022Wells Fargo & CompanyBoost Price TargetOverweight$270.00 ➝ $300.00N/A
4/4/2022OppenheimerBoost Price Target$305.00 ➝ $350.00Low
3/23/2022HC WainwrightReiterated RatingBuy$275.00High
2/3/2022Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$269.00Medium
1/27/2022Wolfe ResearchBoost Price TargetOutperform$271.00 ➝ $282.00Low
1/27/2022JPMorgan Chase & Co.Boost Price TargetOverweight$260.00 ➝ $288.00Low
1/27/2022Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$268.00 ➝ $269.00Low
1/27/2022Stifel NicolausBoost Price TargetHold$213.00 ➝ $222.00Low
1/27/2022Morgan StanleyBoost Price TargetUnderweight$203.00 ➝ $208.00Low
1/20/2022BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$202.00 ➝ $274.00Medium
12/23/2021Evercore ISIReiterated RatingBuy$265.00Low
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$270.00Low
12/2/2021Royal Bank of CanadaBoost Price TargetFair Value ➝ Outperform$250.00 ➝ $265.00Low
11/18/2021BMO Capital MarketsInitiated CoverageMarket Perform$202.00Medium
11/18/2021Piper SandlerDowngradeOverweight ➝ Neutral$323.00 ➝ $218.00Low
11/3/2021Royal Bank of CanadaBoost Price TargetOutperform$246.00 ➝ $250.00High
9/9/2021Stifel NicolausDowngradeBuy ➝ Hold$244.00 ➝ $213.00Medium
9/7/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight$202.00High
7/30/2021Morgan StanleyLower Price TargetEqual Weight$205.00 ➝ $202.00Low
7/30/2021Royal Bank of CanadaBoost Price TargetOutperform$246.00 ➝ $248.00Low
7/30/2021SVB LeerinkBoost Price TargetUnderperform$170.00 ➝ $175.00Low
7/30/2021Piper SandlerBoost Price TargetOverweight$261.00 ➝ $323.00Low
7/20/2021SVB LeerinkDowngradeMarket Perform ➝ Underperform$200.00 ➝ $170.00Low
7/19/2021Wolfe ResearchInitiated CoverageOutperform$252.00Low
6/30/2021Raymond JamesInitiated CoverageMarket PerformLow
6/14/2021Truist FinancialBoost Price TargetBuy$305.00 ➝ $331.00Low
6/14/2021Piper SandlerLower Price TargetOverweight$347.00 ➝ $261.00Low
6/14/2021SVB LeerinkLower Price TargetReduce ➝ Market Perform$250.00 ➝ $200.00Low
6/13/2021Evercore ISIReiterated RatingBuyLow
6/11/2021Stifel NicolausLower Price TargetBuy$277.00 ➝ $244.00High
6/11/2021The Goldman Sachs GroupLower Price TargetBuy$358.00 ➝ $307.00High
6/11/2021BarclaysLower Price TargetOverweight$302.00 ➝ $285.00High
6/11/2021Cantor FitzgeraldLower Price TargetOverweight$285.00 ➝ $281.00High
6/11/2021Morgan StanleyLower Price TargetEqual Weight$254.00 ➝ $205.00High
6/11/2021Robert W. BairdLower Price TargetOutperform$252.00 ➝ $240.00High
6/11/2021Royal Bank of CanadaLower Price TargetPositive ➝ Outperform$262.00 ➝ $242.00High
6/11/2021Daiwa Capital MarketsDowngradeOutperform ➝ Neutral$210.00High
5/3/2021Morgan StanleyBoost Price TargetEqual Weight$253.00 ➝ $254.00Low
4/26/2021Morgan StanleyBoost Price TargetEqual Weight$253.00 ➝ $254.00N/A
4/19/2021Morgan StanleyBoost Price TargetEqual Weight$251.00 ➝ $253.00Low
4/11/2021Royal Bank of CanadaReiterated RatingBuyLow
2/23/2021Robert W. BairdUpgradeNeutral ➝ Outperform$220.00 ➝ $252.00Medium
2/2/2021BMO Capital MarketsLower Price TargetOutperform$302.00 ➝ $284.00Low
2/2/2021Credit Suisse GroupLower Price TargetOutperform$285.00 ➝ $280.00Low
2/2/2021SVB LeerinkLower Price TargetMarket Perform$257.00 ➝ $250.00Low
2/2/2021Piper SandlerBoost Price TargetOverweight$307.00 ➝ $347.00Low
2/2/2021HC WainwrightLower Price TargetBuy$315.00 ➝ $275.00Low
1/19/2021Morgan StanleyBoost Price TargetEqual Weight$249.00 ➝ $251.00Low
12/30/2020Daiwa Capital MarketsInitiated CoverageOutperform$250.00N/A
12/11/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
11/30/2020Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$247.00 ➝ $267.00Low
11/20/2020Sanford C. BernsteinInitiated CoverageOutperform$275.00Low
11/1/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
10/30/2020Piper SandlerLower Price TargetOverweight$327.00 ➝ $307.00Low
10/30/2020Credit Suisse GroupLower Price TargetOutperform$292.00 ➝ $285.00Low
10/30/2020SVB LeerinkLower Price TargetMarket Perform$267.00 ➝ $257.00High
10/28/2020UBS GroupInitiated CoverageBuy$287.00Low
10/26/2020Needham & Company LLCReiterated RatingHoldMedium
10/19/2020Morgan StanleyLower Price TargetEqual Weight$281.00 ➝ $249.00Medium
10/15/2020Truist FinancialLower Price Target$330.00 ➝ $305.00High
10/15/2020SVB LeerinkLower Price TargetMarket Perform$283.00 ➝ $267.00High
10/13/2020Morgan StanleyLower Price TargetEqual Weight$300.00 ➝ $281.00Low
9/18/2020Maxim GroupReiterated RatingHoldHigh
8/24/2020SVB LeerinkBoost Price TargetNeutral ➝ Market Perform$274.00 ➝ $283.00Medium
7/31/2020Cantor FitzgeraldBoost Price TargetOverweight$293.00 ➝ $305.00High
7/31/2020SVB LeerinkBoost Price TargetMarket Perform$263.00 ➝ $274.00High
7/31/2020HC WainwrightReiterated RatingBuy$295.00 ➝ $315.00High
7/31/2020Piper SandlerBoost Price TargetOverweight$302.00 ➝ $327.00High
7/20/2020Credit Suisse GroupBoost Price TargetOutperform$298.00 ➝ $328.00High
7/16/2020CowenBoost Price TargetOutperform$265.00 ➝ $300.00Low
7/14/2020Jefferies Financial GroupBoost Price TargetBuy$295.00 ➝ $340.00High
7/8/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$277.00 ➝ $300.00Medium
7/2/2020The Goldman Sachs GroupBoost Price TargetPositive ➝ Conviction-Buy$290.00 ➝ $330.00Low
6/24/2020SunTrust BanksBoost Price TargetBuy$285.00 ➝ $330.00High
6/12/2020CitigroupBoost Price TargetTop Pick ➝ Buy$305.00 ➝ $325.00Low
5/15/2020ArgusBoost Price TargetBuy$270.00 ➝ $320.00High
5/1/2020CitigroupBoost Price TargetBuy$265.00 ➝ $305.00Medium
4/30/2020Credit Suisse GroupReiterated RatingBuy$298.00Medium
4/30/2020CfraBoost Price TargetBuy$286.00 ➝ $297.00Low
4/30/2020GuggenheimBoost Price TargetBuy$266.00 ➝ $290.00High
4/30/2020BMO Capital MarketsBoost Price TargetOutperform$279.00 ➝ $283.00High
4/30/2020Stifel NicolausBoost Price TargetBuy$275.00 ➝ $285.00High
4/30/2020OppenheimerBoost Price TargetOutperform$265.00 ➝ $305.00High
4/30/2020Morgan StanleyBoost Price TargetOverweight$258.00 ➝ $277.00High
4/30/2020SVB LeerinkBoost Price TargetMarket Perform$224.00 ➝ $263.00High
4/30/2020JMP SecuritiesBoost Price TargetMarket Outperform$255.00 ➝ $285.00High
4/30/2020HC WainwrightBoost Price TargetBuy$270.00 ➝ $295.00High
4/28/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$250.00 ➝ $260.00High
4/27/2020Piper SandlerReiterated RatingBuy$300.00High
4/15/2020Morgan StanleyBoost Price TargetOverweight$251.00 ➝ $258.00Medium
3/27/2020Piper SandlerReiterated RatingBuy$300.00High
3/12/2020Wolfe ResearchInitiated CoverageOutperform$282.00High
3/11/2020Cantor FitzgeraldReiterated RatingOverweight$262.00 ➝ $275.00Medium
3/4/2020BarclaysInitiated CoverageOverweight$271.00High
3/3/2020CowenReiterated RatingBuy$260.00Medium
3/2/2020ArgusBoost Price TargetPositive ➝ Buy$248.00 ➝ $270.00High
2/2/2020Evercore ISIReiterated RatingHold$270.00Medium
1/31/2020Piper SandlerBoost Price Target$284.00 ➝ $300.00Medium
1/31/2020Bank of AmericaReiterated RatingBuy$250.00 ➝ $295.00High
1/31/2020Needham & Company LLCReiterated RatingHoldHigh
1/31/2020Morgan StanleyBoost Price TargetOverweight$250.00 ➝ $251.00Low
1/31/2020Stifel NicolausBoost Price TargetBuy$243.00 ➝ $275.00High
1/31/2020Royal Bank of CanadaBoost Price TargetOutperform$240.00 ➝ $260.00High
1/31/2020CfraBoost Price TargetBuy$237.00 ➝ $286.00High
1/31/2020Credit Suisse GroupBoost Price TargetOutperform$253.00 ➝ $258.00High
1/31/2020SunTrust BanksReiterated RatingBuy$285.00High
1/31/2020JPMorgan Chase & Co.Boost Price TargetOverweight$247.00 ➝ $260.00High
1/31/2020HC WainwrightBoost Price TargetBuy$220.00 ➝ $270.00High
1/31/2020Robert W. BairdDowngradeOutperform ➝ Neutral$210.00 ➝ $230.00High
1/14/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
1/9/2020BMO Capital MarketsBoost Price Target$248.00 ➝ $268.00Low
1/8/2020OppenheimerBoost Price TargetOutperform$230.00 ➝ $265.00Low
1/6/2020Piper Jaffray CompaniesBoost Price TargetOverweight$247.00 ➝ $284.00N/A
1/2/2020Raymond JamesDowngradeOutperform ➝ Market PerformLow
12/18/2019JPMorgan Chase & Co.Boost Price TargetOverweight$218.00 ➝ $247.00Low
12/16/2019ArgusBoost Price TargetBuy$248.00Medium
12/13/2019Credit Suisse GroupUpgradeBuy$231.00Low
11/20/2019BMO Capital MarketsBoost Price TargetOutperform ➝ Positive$248.00Low
11/19/2019CowenReiterated RatingBuyLow
11/19/2019GuggenheimUpgradeNeutral ➝ Buy$252.00High
11/12/2019SunTrust BanksInitiated CoverageBuy$235.00Medium
11/4/2019Credit Suisse GroupReiterated RatingBuy$228.00Low
11/1/2019Maxim GroupReiterated RatingHoldHigh
10/31/2019Piper Jaffray CompaniesBoost Price TargetOverweight$230.00 ➝ $247.00High
10/22/2019Credit Suisse GroupBoost Price TargetOverweight$213.00 ➝ $221.00Low
10/22/2019SVB LeerinkBoost Price TargetMarket Perform$186.00 ➝ $203.00High
10/22/2019CitigroupBoost Price TargetBuy$205.00 ➝ $225.00High
10/21/2019BMO Capital MarketsSet Price TargetBuy$232.00Medium
10/21/2019Jefferies Financial GroupSet Price TargetBuy$220.00Medium
10/21/2019CowenSet Price TargetBuy$220.00Medium
10/21/2019Robert W. BairdSet Price TargetBuy$210.00Medium
10/21/2019JPMorgan Chase & Co.Set Price TargetBuy$218.00Medium
10/16/2019Bank of AmericaInitiated CoverageBuy$220.00Medium
9/23/2019Jefferies Financial GroupBoost Price Target$210.00 ➝ $220.00Medium
9/6/2019Morgan StanleyBoost Price TargetOverweight$215.00 ➝ $240.00Low
9/3/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$226.00 ➝ $254.00High
8/12/2019Royal Bank of CanadaSet Price TargetBuy$213.00Low
8/2/2019Maxim GroupReiterated RatingHoldLow
8/1/2019Credit Suisse GroupBoost Price TargetOutperform$209.00 ➝ $213.00Low
8/1/2019Piper Jaffray CompaniesBoost Price TargetOverweight$217.00 ➝ $230.00Low
8/1/2019Stifel NicolausBoost Price TargetBuy$205.00 ➝ $211.00Low
8/1/2019JPMorgan Chase & Co.Reiterated RatingBuy$212.00High
8/1/2019HC WainwrightReiterated RatingBuy$220.00High
8/1/2019Needham & Company LLCDowngradeBuy ➝ HoldHigh
7/31/2019CowenSet Price TargetBuy$220.00N/A
6/2/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
5/23/2019The Goldman Sachs GroupReiterated RatingBuy$220.00Low
5/23/2019CitigroupReiterated RatingBuy ➝ Buy$205.00Low
5/20/2019Credit Suisse GroupInitiated CoverageOutperform$209.00 ➝ $209.00Medium
5/1/2019Needham & Company LLCReiterated RatingBuy$195.00Low
5/1/2019JPMorgan Chase & Co.Reiterated RatingBuy$209.00High
4/30/2019CowenReiterated RatingBuy$220.00High
4/11/2019Evercore ISIInitiated CoverageIn-Line$183.00Low
3/26/2019William BlairUpgradeMarket Perform ➝ Outperform$183.85Medium
3/19/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$185.40Medium
3/7/2019OppenheimerBoost Price TargetOutperform ➝ Outperform$200.00 ➝ $230.00Low
3/6/2019CowenReiterated RatingBuy$220.00Medium
3/6/2019Maxim GroupReiterated RatingHoldMedium
2/6/2019BMO Capital MarketsBoost Price TargetOutperform$234.00High
2/6/2019Maxim GroupDowngradeBuy ➝ HoldHigh
1/4/2019CitigroupLower Price TargetBuy ➝ Buy$206.00 ➝ $205.00Medium
1/2/2019Raymond JamesDowngradeOutperform ➝ Market Perform$165.71Low
12/19/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$211.00 ➝ $210.00High
12/17/2018GuggenheimInitiated CoverageNeutralMedium
12/17/2018Cantor FitzgeraldReiterated RatingBuy$217.00High
11/27/2018OppenheimerSet Price TargetBuy$200.00High
11/27/2018Cantor FitzgeraldReiterated RatingBuy$217.00Low
10/26/2018Piper Jaffray CompaniesLower Price TargetOverweight$217.00Medium
10/26/2018HC WainwrightUpgradeNeutral ➝ Buy$220.00High
10/25/2018BMO Capital MarketsLower Price TargetOutperform$204.00 ➝ $192.00High
10/25/2018Raymond JamesSet Price TargetBuy$211.00 ➝ $201.00High
10/24/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium
10/2/2018Raymond JamesInitiated CoverageBuyLow
10/1/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$217.00Medium
8/28/2018ArgusBoost Price TargetBuy ➝ Average$200.00High
8/7/2018Stifel NicolausBoost Price TargetBuy$182.00 ➝ $200.00Medium
7/30/2018CitigroupBoost Price TargetBuy ➝ Buy$203.00 ➝ $206.00Medium
7/26/2018Royal Bank of CanadaReiterated RatingBuy$203.00Medium
7/26/2018UBS GroupBoost Price TargetNeutral ➝ Neutral$183.00 ➝ $188.00High
7/26/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$207.00 ➝ $211.00High
7/26/2018OppenheimerBoost Price TargetOutperform$180.00 ➝ $200.00High
7/26/2018Piper Jaffray CompaniesBoost Price TargetOverweight$230.00High
7/26/2018BMO Capital MarketsBoost Price TargetOutperform$204.00High
7/16/2018Jefferies Financial GroupBoost Price TargetBuy$210.00Low
7/1/2018JPMorgan Chase & Co.Reiterated RatingBuyLow
6/12/2018ArgusSet Price TargetBuy ➝ Buy$172.00Low
4/27/2018CowenReiterated RatingBuy$200.00Low
4/27/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$200.00 ➝ $207.00Low
4/27/2018Maxim GroupReiterated RatingBuy$200.00High
3/5/2018Maxim GroupBoost Price TargetBuy ➝ Buy$195.00 ➝ $200.00Medium
2/23/2018ArgusSet Price TargetBuy ➝ Buy$194.00High
2/13/2018JMP SecuritiesReiterated RatingMarket Outperform ➝ Outperform$200.00 ➝ $211.00Low
2/13/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$195.00 ➝ $196.00Low
2/13/2018HC WainwrightReiterated RatingHold$103.00Low
2/2/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$198.00 ➝ $200.00Medium
2/1/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$180.00 ➝ $197.00High
2/1/2018HC WainwrightReiterated RatingHold$103.00High
2/1/2018CitigroupReiterated RatingBuyHigh
2/1/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Buy$184.00 ➝ $191.00High
2/1/2018SVB LeerinkReiterated RatingOutperform$175.00 ➝ $190.00High
2/1/2018Royal Bank of CanadaBoost Price TargetOutperform$200.00High
2/1/2018Jefferies Financial GroupReiterated RatingBuy$195.00High
2/1/2018BarclaysBoost Price TargetOverweight ➝ Overweight$180.00 ➝ $200.00High
1/31/2018Maxim GroupReiterated RatingBuy$195.00Low
1/23/2018Bank of AmericaReiterated RatingBuy$180.00Low
1/9/2018JPMorgan Chase & Co.Reiterated RatingBuyLow
1/5/2018Bank of AmericaUpgradeNeutral ➝ Buy$180.00Low
1/4/2018OppenheimerBoost Price TargetOutperform$175.00 ➝ $190.00Low
12/12/2017Deutsche Bank AktiengesellschaftInitiated CoverageBuy$175.00High
12/11/2017CowenReiterated RatingBuy$200.00Low
10/27/2017Royal Bank of CanadaReiterated RatingBuyN/A
10/27/2017Needham & Company LLCReiterated RatingBuy$195.00N/A
10/27/2017Robert W. BairdReiterated RatingBuyN/A
10/26/2017HC WainwrightReiterated RatingHold$85.00N/A
10/26/2017Maxim GroupReiterated RatingBuy$195.00N/A
10/26/2017Piper Jaffray CompaniesReiterated RatingOverweight$205.00N/A
10/18/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$175.00 ➝ $181.00N/A
9/29/2017DA DavidsonInitiated CoverageBuy$200.00Low
9/29/2017BTIG ResearchInitiated CoverageBuy ➝ Buy$200.00Medium
9/27/2017BMO Capital MarketsReiterated RatingBuyLow
9/17/2017Needham & Company LLCReiterated RatingBuy$195.00Low
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$175.00Low
8/22/2017Jefferies Financial GroupReiterated RatingBuyHigh
8/1/2017CowenReiterated RatingBuyMedium
8/1/2017ArgusBoost Price TargetBuy$71.46 ➝ $175.00Low
7/27/2017BMO Capital MarketsReiterated RatingOutperform$180.00 ➝ $182.00Low
7/27/2017OppenheimerBoost Price TargetOutperform$150.00 ➝ $175.00Medium
7/27/2017JPMorgan Chase & Co.Set Price TargetBuy$175.00 ➝ $184.00High
7/27/2017Maxim GroupSet Price TargetBuy$195.00High
7/22/2017Morgan StanleyReiterated RatingOverweight$153.00 ➝ $190.00Low
7/21/2017Robert W. BairdReiterated RatingOutperform$136.00 ➝ $171.00Low
7/21/2017Needham & Company LLCReiterated RatingBuy$155.00 ➝ $195.00Low
7/21/2017BMO Capital MarketsReiterated RatingOutperform$132.00 ➝ $180.00Low
7/21/2017CitigroupReiterated RatingBuy$135.00 ➝ $190.00Low
7/19/2017JPMorgan Chase & Co.Set Price TargetBuy$129.00 ➝ $175.00Low
7/19/2017Maxim GroupSet Price TargetBuy$143.00 ➝ $195.00Low
7/19/2017UBS GroupDowngradeBuy ➝ Neutral$135.00 ➝ $174.00High
7/19/2017Credit Suisse GroupBoost Price TargetOutperform$125.00 ➝ $195.00High
7/19/2017JMP SecuritiesReiterated RatingOutperformHigh
7/19/2017Raymond JamesUpgradeMarket Perform ➝ Outperform$181.00High
7/19/2017Piper Jaffray CompaniesBoost Price TargetOverweight$194.00High
7/19/2017Jefferies Financial GroupReiterated RatingBuy$155.00 ➝ $185.00High
7/19/2017HC WainwrightReiterated RatingHold$85.00High
7/19/2017Janney Montgomery ScottUpgradeNeutral ➝ Buy$98.00High
7/19/2017CowenUpgradeMarket Perform ➝ Outperform$105.00 ➝ $200.00High
7/19/2017BarclaysUpgradeEqual Weight ➝ Overweight$115.00 ➝ $180.00High
7/18/2017Stifel NicolausBoost Price TargetBuy ➝ Buy$130.00 ➝ $154.00High
7/10/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$155.00High
7/6/2017CowenReiterated RatingMarket Perform$105.00Low
6/23/2017Needham & Company LLCUpgradeHold ➝ Buy$155.00Medium
6/22/2017SVB LeerinkReiterated RatingOutperformMedium
6/9/2017Jefferies Financial GroupReiterated RatingBuy$126.00Low
6/2/2017CIBCUpgradeMarket Perform ➝ OutperformLow
6/2/2017OppenheimerUpgradeMarket Perform ➝ Outperform$150.00Medium
(Data available from 5/25/2017 forward)

News Sentiment Rating

0.18 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 17 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 4 very negative mentions
10/27/2021
  • 13 very positive mentions
  • 27 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
11/26/2021
  • 8 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
12/26/2021
  • 10 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
1/25/2022
  • 11 very positive mentions
  • 45 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
2/24/2022
  • 14 very positive mentions
  • 19 positive mentions
  • 5 negative mentions
  • 10 very negative mentions
3/26/2022
  • 8 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
4/25/2022
  • 11 very positive mentions
  • 60 positive mentions
  • 11 negative mentions
  • 4 very negative mentions
5/25/2022

Current Sentiment

  • 11 very positive mentions
  • 60 positive mentions
  • 11 negative mentions
  • 4 very negative mentions

Recent Stories by Sentiment

Vertex Pharmaceuticals logo
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $270.84
Low: $267.82
High: $273.19

50 Day Range

MA: $263.82
Low: $234.96
High: $290.93

52 Week Range

Now: $270.84
Low: $176.36
High: $292.75

Volume

1,880,655 shs

Average Volume

1,728,636 shs

Market Capitalization

$69.27 billion

P/E Ratio

28.26

Dividend Yield

N/A

Beta

0.55

Frequently Asked Questions

What sell-side analysts currently cover shares of Vertex Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on Vertex Pharmaceuticals in the last twelve months: Barclays PLC, BMO Capital Markets, Cantor Fitzgerald, Daiwa Capital Markets, Evercore ISI, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, Truist Financial Co., UBS Group AG, Wells Fargo & Company, Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for VRTX.

What is the current price target for Vertex Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Vertex Pharmaceuticals in the last year. Their average twelve-month price target is $277.68, suggesting a possible upside of 2.5%.
View the latest price targets for VRTX.

What is the current consensus analyst rating for Vertex Pharmaceuticals?

Vertex Pharmaceuticals currently has 8 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VRTX will outperform the market and that investors should add to their positions of Vertex Pharmaceuticals.
View the latest ratings for VRTX.

How do I contact Vertex Pharmaceuticals' investor relations team?

Vertex Pharmaceuticals' physical mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company's listed phone number is (617) 341-6100 and its investor relations email address is [email protected] The official website for Vertex Pharmaceuticals is www.vrtx.com. Learn More about contacing Vertex Pharmaceuticals investor relations.